Skip to main content
Article thumbnail
Location of Repository

Efficacy of trabectedin in metastatic solitary fibrous tumor

By Xavier Pivot, Laura Mansi, Stephanie Servagi-Vernat, Delphine Delroeux, Julien Pauchot, Lionel Aherfi, Nicolas Isambert, Antoine Thiery-Vuillemin, Christine Fagnoni-Legat, Elsa Kalbacher and Loic Chaigneau

Abstract

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19 %, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine andor ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option

Topics: metastatic solitary fibrous tumor, trabectedin, LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, LCC:RC254-282, LCC:Internal medicine, LCC:RC31-1245, LCC:Medicine, LCC:R, DOAJ:Oncology, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: PAGEPress Publications
Year: 2011
DOI identifier: 10.4081/rt.2011.e29
OAI identifier: oai:doaj.org/article:951a9fbb7aca424f83d3fbb6e2af6323
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://doaj.org/search?source=... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.